Introduction {#s0001}
============

*Mycobacterium abscessus* (*M. abscessus*) is a rapidly growing non-tuberculous mycobacterium that causes progressive inflammatory lung damage and a significant decline in lung function in patients with structural lung diseases such as cystic fibrosis and bronchiectasis.[@cit0001] Pulmonary *M. abscessus* infections are notoriously difficult to treat, necessitating prolonged multidrug therapy due to the intrinsic resistance of the organism to most anti-mycobacterial drugs.[@cit0002] The increasing prevalence of pulmonary disease due to *M. abscessus* supports the urgent need for more effective treatment regimens.

Due to its broad spectrum of antibacterial activity, imipenem is currently recommended as one drug of choice for treating *M. abscessus* pulmonary disease. Meta-analysis involving 14 eligible studies showed that treatment with imipenem correlated with clinical success.[@cit0003] Imipenem combined with other antibiotics exerted a synergistic or additive effect, which contributed to this success.[@cit0004]--[@cit0006] Developing resistance to imipenem, however, is a major health concern. Recently, for example, two groups reported the high MIC~50~ (16 mg/L) and MIC~90~ (16--32 mg/L) of imipenem for *M. abscessus*.[@cit0007],[@cit0008] Moreover, bacterial resistance to imipenem in some studies was more than 60%, clearly limiting the clinical application of imipenem in treating *M. abscessus* infections.[@cit0009]--[@cit0011]

N,N,N',N'-tetrakis (2-pyridylmethyl) ethane-1,2-diamine (TPEN) is a specific zinc chelator and metallo-β-lactamases (MBLs) inhibitor shown to increase the sensitivity of certain bacteria (eg, *K. pneumoniae, S. maltophilia* and *E. meningoseptica*) to carbapenems in vitro and in vivo by suppressing MBLs activity.[@cit0012],[@cit0013] There are no reports, however, concerning TPEN and the resistance of *M. abscessus* to imipenem. In the study described herein, one hundred ninety-four clinical, *M. abscessus* isolates were collected from patients with lung diseases; the activity and MIC of imipenem toward the isolates were determined. The MIC of imipenem and the number of resistant isolates decreased remarkably in the presence TPEN, presumably as a result of the inhibitory effect of TPEN on MBLs activity. To our knowledge, this is the first study to explore the ability of TPEN to increase the susceptibility of *M. abscessus* to imipenem treatment. The results improve our understanding of imipenem resistance and suggest new strategies to enhance treatment of *M. abscessus* infections.

Materials and Methods {#s0002}
=====================

Ethics Statement {#s0002-s2001}
----------------

As the study only concerned laboratory testing of mycobacteria without the direct involvement of human subjects, ethics approval was not sought.

Bacteria {#s0002-s2002}
--------

One hundred and nighty-four clinical isolates were collected as described previously from the sputum and bronchoalveolar lavage fluid samples of patients with lung infections in Shanghai Pulmonary Hospital.[@cit0011],[@cit0014] Isolates were initially screened for non-tuberculosis mycobacteria by growth in MGIT960 culture medium and resistance to p-nitrobenzoic acid. *M. abscessus* was identified by sequencing the *rpoB* and *erm*(41) genes. Isolates were stored at −80°C in trypticase soy broth containing 40% glycerol. Fresh cultures were started for each experiment. The antibiotic-sensitive reference strain, *M. abscessus* ATCC 19977 was purchased from the American Type Culture Collection (ATCC; Manassas, VA) and grown to mid-log phase in Middle brook 7H9 medium (Becton Dickinson, Cockeysville, MD) supplemented with 0.2% glycerol, 10% oleic acid-albumin-dextrose-catalase (OADC) enrichment (Becton Dickinson) and 0.05% Tween 80 (BBL Life Sciences; 7H9sB).

Chemical Reagents {#s0002-s2003}
-----------------

Imipenem (GlpBio, Montclair, CA, USA), sulbactam, avibactam, relebactam and TPEN (MedChemExpress, Monmouth Junction, NJ, USA) were used alone or in combination. Stock solutions of imipenem (2048 μg/mL), sulbactam (9132.5 μg/mL), avibactam (9132.5 μg/mL), and relebactam (9132.5 μg/mL) were prepared in sterile water. TPEN, dissolved in 100% DMSO (32 mg/mL stock solution), was diluted in sterile water to obtain the desired working concentration.

Susceptibility Testing {#s0002-s2004}
----------------------

The sensitivity of *M. abscessus* to imipenem with or without TPEN was determined by the microdilution method in cation-adjusted Muller Hinton Broth (BD Bioscience, Drachten, The Netherlands); the results were assessed after 3 days. The breakpoints of imipenem MICs were interpreted according to Clinical and Laboratory Standards Institute (CLSI)-M24-A2 where ≤4 mg/L = susceptible, 8--16 mg/L = resistance intermediate, and ≥32 mg/L = resistant. *Mycobacterium peregrinum* (ATCC700686) served as the control reference strain.

Synergy Testing {#s0002-s2005}
---------------

Synergy between imipenem and TPEN was assessed by the broth microdilution checkerboard method using the *M. abscessus* reference strain ATCC19977 and 61 clinical isolates (30 imipenem-resistant, 23 imipenem-resistance intermediate and 8 imipenem-susceptible). All synergy tests were performed in cation-adjusted Muller Hinton Broth. Drug interactions were interpreted according to the fractional inhibitory concentration index (FICI). The fractional inhibitory concentration (FIC) was calculated using the formula FIC = (MIC~a~ combination/MIC~A~ alone) + (MIC~b~ combination/MIC~B~ alone). The minimum FIC for each combination was defined as the FIC index (FICI).[@cit0008] Drug interactions were classified as: synergistic, FICI = ≤0.5; no interaction, FICI = \>0.5--4.0; or antagonistic, FICI = \>4.0.

Time--Kill Kinetics (TK) Assays {#s0002-s2006}
-------------------------------

TK assays were performed using the *M. abscessus* reference strain ATCC19977 and an imipenem-resistant clinical isolate, A189. Five milliliter tubes of 7H9sB containing imipenem or TPEN alone, or both drugs in various combination at 0.5×MIC, 1×MIC or 2×MIC were inoculated with 5×10^5^ CFUs of bacteria growing exponentially, and the bacteria were incubated at 37°C with shaking (100 rpm). The bacteria were enumerated after 0, 1, 2, 3 and 5 days incubation by plating serial dilutions of culture aliquots on lysogeny broth agar plates; CFUs were counted after an additional 5 days incubation at 37°C. All assays were performed in triplicate. A bactericidal effect was defined as ≥2 log reduction in CFUs.

Exploration of the Relationship Between MBLs and Imipenem Resistance in *M. abscessus* {#s0002-s2007}
--------------------------------------------------------------------------------------

β-lactamase-dependent degradation is the major mechanism conferring microbial resistance to imipenem. EDTA, like TPEN, is a well-documented MBLs inhibitor. The growth of imipenem-resistant, -resistance intermediate and -sensitive isolates surrounding imipenem disks impregnated or not impregnated with EDTA on agar plates was assessed in order to substantiate the potential role of MBLs in conferring imipenem resistance upon *M. abscessus*. Middlebrook 7H10 agar plates (7.0 cm) were prepared in our laboratory using dehydrated products from Becton Dickinson. Bacteria were grown to mid-log phase, and fresh cultures were used to prepare suspensions at a McFarland turbidity of 0.5. Two OXOID imipenem antimicrobial susceptibility disks (10 μg; Thermo Fisher Scientific, Waltham, MA, USA) were placed \>30 mm apart onto 7H10 agar plates, 0.03125 M EDTA was added to one of the disks, and the plates were incubated for 4 days at 37 ^o^C. A zone ≥5 mm diameter around the imipenem-EDTA disk compared to the imipenem disk alone was considered positive for MBLs.[@cit0015] The ability of additional β-lactamase inhibitors, which do not target MBLs (ie, sulbactam, avibactam and relebactam), to synergize with imipenem and inhibit the growth of an imipenem-resistant isolate was accessed in a similar fashion.

Results {#s0003}
=======

Imipenem Susceptibility Profile of Clinical *M. abscessus* Isolates {#s0003-s2001}
-------------------------------------------------------------------

The MICs of imipenem for 194 *M. abscessus* isolates ranged from 4 to 256 mg/L, MIC~50~ = 16 mg/L, MIC~90~ = 64 mg/L ([Figure 1](#f0001){ref-type="fig"}). Of all the isolates, 183 (94.3%) were not susceptible to imipenem; 87 (44.8%) of these were intermediately resistant and 96 (49.5%) were totally resistant. This demonstrates the relatively high resistance rate of clinical *M. abscessus* isolates to imipenem.Figure 1MIC of imipenem for 194 clinical *M. abscessus* isolates.

Imipenem and TPEN Act Synergistically {#s0003-s2002}
-------------------------------------

The sensitivity of ATCC 19977 and the sixty-one clinical isolates to imipenem and TPEN tested separately was determined initially. The MIC~50~ and MIC~90~ of imipenem and TPEN were 16 and 64 mg/L, and 64 and 128 mg/L, respectively. Subsequently, synergy between imipenem and TPEN was assessed. Using a combination of TPEN and imipenem, synergy was demonstrable in 100% (30/30) of the imipenem-resistant and 79.2% (19/24) of the imipenem-resistance intermediate isolates; no synergy was observed in the imipenem-sensitive isolates ([Table 1](#t0001){ref-type="table"}). The data for each isolate is shown in [[Table S1](https://www.dovepress.com/get_supplementary_file.php?f=267552.docx)]{.ul}. Imipenem exhibited a remarkable decrease in MIC~50~ (from 16 to 4 mg/L) and MIC~90~ (from 64 to 8 mg/L) when used in combination with TPEN. The proportion of imipenem-resistant isolates also decreased from 48.4% to 0% ([Figure 2](#f0002){ref-type="fig"}). Furthermore, when TPEN was tested in combination with a variety of other antibiotics commonly used to treat *M. abscessus* infections (ie, clarithromycin, amikacin, cefoxitin, moxifloxacin, linezolid and tigecycline), no synergy was found ([[Table S2](https://www.dovepress.com/get_supplementary_file.php?f=267552.docx)]{.ul}). Therefore, synergy between TPEN and imipenem appears specific.Table 1Imipenem and TPEN Act Synergistically to Inhibit the Growth of Imipenem-Resistant *M. abscessus\**IsolatesImipenemImipenem + TPENTPENTPEN + ImipenemFICIPercent SynergyResistant (n=30)32--1284--1632--2568--320.1875--0.5100% (30/30)Intermediate (n=24)8--161--416--1284--320.25--0.7579.2% (19/24)81--416--1284--320.375--0.7550% (5/10)162--432--1284--160.25--0.5100% (14/14)Sensitive (n=8)41--416--644--320.75--1.250% (0/8)[^2] Figure 2Susceptibility of *M. abscessus* isolates (n=62) to imipenem with or without TPEN. The data above each bar are the percentage of isolates.

Time--Kill Studies {#s0003-s2003}
------------------

Consistent with the results demonstrating synergy, the addition of TPEN increased the bactericidal activity of imipenem in contrast to exerting only a weak bacteriostatic effect when TPEN was added alone. Bactericidal synergy in TK assays was defined as ≥2 log reduction in CFUs compared to 2×MIC imipenem alone. The bactericidal effect of IMI + TPEN 2×MIC was evident on day 3 for ATCC19977 ([Figure 3A](#f0003){ref-type="fig"}), while it was demonstrable from days 2 to 5 for the randomly selected imipenem-resistant clinical isolate A189 ([Figure 3B](#f0003){ref-type="fig"}). As such, the combination of TPEN and imipenem appeared to exert a stronger synergistic effect on resistant isolates. Presumably, the re-growth of both ATCC19977 and A189 observed in TK assays after 3 days culture was due to the predominant bactericidal role of imipenem and its degradation in vitro.Figure 3Time--kill kinetic assays. In vitro TK assays were conducted with reference strain ATCC19977 (**A**) and an imipenem-resistant clinical isolate, A189 (**B**). The bacteria were incubated in the presence of either imipenem or TPEN alone, or in combination at the various concentrations shown. The MIC of imipenem for ATCC19977 and A189 was 16 and 32 mg/L, respectively; the MIC of TPEN was 64 mg/L for both. A bactericidal effect was defined as ≥2 log reduction in CFUs compared to 2×MIC imipenem alone in TK assays. \*≥2 log reduction in CFUs.

Relationship Between MBLs and Imipenem Resistance in *M. abscessus* {#s0003-s2004}
-------------------------------------------------------------------

The growth of 30 imipenem-resistant, 23 imipenem-resistance intermediate and 8 imipenem-sensitive isolates on agar plates around imipenem disks impregnated with EDTA further substantiated the presence of MBLs and their role in imipenem resistance. A zone of growth inhibition ≥5 mm larger than the zone surrounding a disk impregnated with imipenem alone was detected in all imipenem-resistant isolates (MIC ≥16 mg/L), 50% of the intermediately resistant isolates (MIC=8 mg/L), and none of the imipenem-sensitive isolates ([Table 2](#t0002){ref-type="table"}, [Figure 4A](#f0004){ref-type="fig"}). These results suggest that the resistance of *M. abscessus* isolates to imipenem is due to MBLs, which are inhibited by the presence of EDTA.Table 2Zone of Inhibition Surrounding Imipenem Disk with or without EDTA\*StrainsImipenem (mm)Imipenem + EDTA (mm)Mean IncreaseRangeMeanRangeMean(mm)Resistant6--10824--282618Intermediate (16mg/L)17--191828--302911Intermediate (8 mg/L)24--272628--31304Sensitive26--282729--32303[^3] Figure 4Detection of metallo-β-lactamases by imipenem-EDTA combined disk method. (**A**) Zones of growth inhibition are shown surrounding imipenem disks impregnated or not impregnated with EDTA on plates inoculated with imipenem-resistant, -resistance intermediate, or -sensitive *M. abscessus* strains. EDTA, ethylenediaminetetraacetic acid; IMI, imipenem. (**B**) The abilities of EDTA, sulbactam, avibactam and relebactam to synergize with imipenem and inhibit the growth of imipenem-resistant (A247) *M. abscessus* were determined and compared. Imipenem disks were impregnated with or without the compound listed; the surrounding zones of growth inhibition are shown. Bacterial growth surrounding disks impregnated with EDTA, sulbactam, avibactam or relebactam alone (plate on the right) serves as the negative control. **^⋆^**Indicates a zone of growth inhibition ≥5 mm larger than the zone surrounding a disk impregnated with imipenem alone.

Sulbactam, avibactam and relebactam are novel β-lactamase inhibitors.[@cit0016] Experiments were undertaken to determine whether these inhibitors could synergize with imipenem to inhibit the growth of *M. abscessus* in a manner analogous to EDTA. Growth of an imipenem-resistant isolate (A247) on agar plates around imipenem disks infused with sulbactam, avibactam or relebactam was equivalent to growth around a disk infused with imipenem alone ([Figure 4B](#f0004){ref-type="fig"}). A significant difference in the zone of inhibition demonstrating synergy was only seen surrounding imipenem disks impregnated with EDTA shown for comparison purposes. These findings indicate that MBLs specifically enhance the resistance of *M. abscessus* to imipenem, other β-lactamases are incapable.

Discussion {#s0004}
==========

Imipenem is one of the most reliable antibiotics used to treat *M. abscessus* infections.[@cit0017],[@cit0018] Recently, however, imipenem-resistant *M. abscessus* has emerged; the underlying resistance mechanism remains to be delineated fully. The present study confirmed the high rate of *M. abscessus* resistance to imipenem based upon analysis of a large number of clinical isolates obtained in mainland China. Imipenem resistance exhibited by these isolates correlated with the presence of MBLs. The presence of TPEN, a zinc chelator which inhibits MBL activity, dramatically reduced the resistance of *M. abscessus* to imipenem.

β-lactam antibiotics are important chemotherapeutic agents used to treat *M. abscessus* infections. One study even proposed treating such infections with two β-lactams, ie, ceftazidime and imipenem, to enhance killing activity.[@cit0019] Imipenem has garnered considerable attention recently due to its association with improved clinical prognoses.[@cit0003] The anti-*M. abscessus* activity exhibited by imipenem in vitro, however, is variable. In the current study, 49.5% of 194 isolates were resistant to imipenem (MIC~50~ = 16 mg/L), a result which is consistent with previous studies.[@cit0007]--[@cit0011] Notably, a high imipenem MIC cannot be equated with poor clinical outcomes since imipenem shows elevated intracellular antimicrobial activity.[@cit0020] Moreover, it exhibits synergism or an additive effect when used in combination with other antibiotics.[@cit0005],[@cit0006] Therefore, resistance to imipenem does not limit its clinical application in treating *M. abscessus* infections.

Degradation by β-lactamase is the major mechanism conferring microbial resistance to imipenem.[@cit0021] MBLs are pan-reactive enzymes that can degrade most classes of β-lactams including antibiotics of last-resort such as carbapenems. The MBLs are a group of enzymes that exhibit catalytic active in the presence of Zn[@cit0002]+ ions. TPEN is a cell-permeable, zinc-specific chelator that functions as a broad-spectrum antimicrobial agent.[@cit0022] TPEN can modulate human monocyte functions that include phagocytosis, oxidative burst, and TNF-α and IL-6 production in response to *Escherichia coli, Staphylococcus aureus* and *Streptococcus pneumoniae*.[@cit0023] Additionally, it prevented death in a mouse model of lethal aspergillus infection.[@cit0024] As such, TPEN exhibits antimicrobial activity both in vitro and in vivo. As a zinc chelator, TPEN is also a potent MBLs inhibitor. Recently, Princip and colleagues found TPEN reversed the MBL-mediated resistance of *K. pneumoniae, S. maltophilia* and *E. meningoseptica* to meropenem *both* in vitro *and* in vivo.[@cit0013] Azumah and colleagues reported that TPEN also rendered carbapenem-resistant Enterobacteriaceae (CRE) susceptible to meropenem.[@cit0025] Notably, TPEN exhibited the greatest activity, assessed in terms of a decrease in the MIC of meropenem, compared to a variety of metal chelators tested.[@cit0024] The relationship between imipenem resistance and the presence of MBLs in *M. abscessus* is proposed for the first time herein. TPEN synergized with imipenem to diminish the growth of imipenem-resistant *M. abscessus* in both synergy testing and TK assays. Synergy was more pronounced in resistant isolates potentially capable of producing MBLs. Presumably, the increase in CFUs observed in TK assays after 2--3 days culture in the presence of imipenem and TPEN was due to the predominant bactericidal role and degradation of imipenem in vitro.[@cit0025]

To date, no drug used clinically affects MBL activity. TPEN is a heavy metal chelator which, unlike comparable chelators such as DTPA and EDTA, is cell permeable. Thus, it promises to be more effective in treating *M. abscessus*, a typical facultative intracellular bacterium. Free intracellular zinc levels were significantly lowered using TPEN.[@cit0023] Immunosuppressed mice infected with *A. fumigatus* demonstrated a 60% survival rate when treated with 5 mg/kg TPEN daily; doses ≤10 mg/kg were well tolerated.[@cit0026],[@cit0027] As such, TPEN may be an effective drug in treating imipenem-resistant *M. abscessus* by virtue of its ability to permeate cells and inhibit MBLs activity.

Experiments involving the extraction and purification of the metalloenzyme proteins from *M. abscessus* are currently ongoing in the laboratory in an effort to demonstrate the direct interaction of TPEN with MBLs. Additional experiments are dedicated to determining the capacity of TPEN to increase the anti-microbial activity of imipenem in animal models of *M. abscessus* infection.

Conclusion {#s0005}
==========

TPEN reduces the resistance of *M. abscessus* to imipenem by inhibiting MBLs activity.
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[^2]: **Notes:** *\**Reference strain ATCC19977 and 61 clinical M. abscessus isolates were divided into imipenem-resistant, -resistance intermediate and -sensitive groups, and the ability of TPEN to synergize with imipenem to inhibit growth was determined. Minimum inhibitory concentrations (or range of concentrations) shown in columns are: imipenem tested alone; imipenem tested in combination with TPEN; TPEN tested alone; TPEN tested in combination with imipenem. FICI ≤0.5 = synergy; FICI \>0.5--4.0 = no drug interaction.

[^3]: **Notes:** \*ATCC19977 and 61 clinical isolates classified as imipenem-resistant, -resistance intermediate or -sensitive were spread onto agar plates. Ten microgram imipenem disks impregnated with or without 0.03125M EDTA were placed on the surface and the plates were incubated for 5 days at 37°C. A zone ≥5 mm diameter surrounding the EDTA-impregnated disk compared to the non-impregnated disk was considered MBLs positive.
